Related Experiment Videos
Topical prostaglandin E2 effects on normal human intraocular pressure.
1University of California, San Francisco.
Journal of Ocular Pharmacology
|January 1, 1988
Summary
Topical prostaglandin E2 (PGE2) eye drops significantly lowered intraocular pressure in healthy volunteers for up to 24 hours. This study suggests PGE2 may be a new treatment for elevated intraocular pressure.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma.
- Novel therapeutic agents for IOP reduction are continuously sought.
Purpose of the Study:
- To evaluate the efficacy and safety of topically administered prostaglandin E2 (PGE2) in reducing IOP in healthy human volunteers.
Main Methods:
- A double-masked, randomized, paired comparison with vehicle control trial was conducted.
- Healthy volunteers received a single drop of 0.02% PGE2 solution.
- Intraocular pressure was measured at baseline and at several time points up to 24 hours post-instillation.
Main Results:
- A statistically significant decrease in IOP was observed at 6 hours, persisting to 24 hours.
- Transient IOP elevation was noted at 1 and 2 hours post-instillation.
- Reported side effects included mild eye ache and photophobia, with transient conjunctival vasodilation; no anterior chamber inflammation was detected.
Conclusions:
- Topical PGE2 effectively lowers IOP in healthy individuals.
- PGE2 or its derivatives represent a potential new class of topical ocular hypotensive agents for managing glaucoma.